Serum amyloid A: A new potential serum marker correlated with the stage of breast cancer.

Previous studies reported that serum amyloid A (SAA) is elevated in patients with tumors, including breast cancer, compared to healthy controls. In addition, the levels of SAA increase gradually with tumor progression. In this study, we investigated the blood SAA level of breast cancer patients, and evaluated its potential as a serum biomarker for the early diagnosis of breast cancer and as a staging estimate. SAA protein was determined by enzyme-linked immunosorbent assay in serum samples from 30 healthy women, 21 women with benign diseases and 118 breast cancer patients who were subdivided into 4 groups based on their clinical characteristics. SAA levels were not statistically different in stage I breast cancer patients compared with the healthy controls and benign breast disease patients. SAA concentrations had medians of 0.63 µg/ml in normal healthy women, 0.76 µg/ml in patients with benign disease (p>0.05) and 0.82 µg/ml in stage I breast cancer patients (p>0.05). By contrast, SAA values in stage Ⅱ, Ⅲ and Ⅳ patients had a significantly higher median compared to those of the healthy, benign breast diseases and stage I groups (p<0.05). Breast cancer patients with lymph node (LN) metastasis or distant metastasis were found to have significantly higher SAA concentrations than those without metastases. SAA is not a suitable marker for early breast cancer diagnosis, but its level is correlated with the stage of breast cancer. Thus, it may be a good candidate marker for the staging and prognosis of breast cancer.

[1]  C. Ulrich,et al.  Dietary fiber is associated with circulating concentrations of C-reactive protein in breast cancer survivors: the HEAL study , 2011, Breast Cancer Research and Treatment.

[2]  Choon-Sik Park,et al.  Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. , 2011, Journal of proteome research.

[3]  K. Tang,et al.  Pleiotropic regulation of macrophage polarization and tumorigenesis by formyl peptide receptor-2 , 2011, Oncogene.

[4]  C. Ulrich,et al.  Postdiagnosis Diet Quality Is Inversely Related to a Biomarker of Inflammation among Breast Cancer Survivors , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[5]  G. Kovacs,et al.  Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. , 2010, European urology.

[6]  T. Rutherford,et al.  Serum amyloid A , 2010, Cancer.

[7]  D. Pomp,et al.  Dietary fat alters pulmonary metastasis of mammary cancers through cancer autonomous and non-autonomous changes in gene expression , 2010, Clinical & Experimental Metastasis.

[8]  C. Ulrich,et al.  Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Lisa H Cazares,et al.  Serum proteomic biomarker discovery reflective of stage and obesity in breast cancer patients. , 2009, Journal of the American College of Surgeons.

[10]  E. Ratner,et al.  Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer , 2009, British Journal of Cancer.

[11]  C. Ulrich,et al.  Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors , 2009, Breast Cancer Research and Treatment.

[12]  M. Redondo,et al.  Monitoring indicators of health care quality by means of a hospital register of tumours. , 2008, Journal of evaluation in clinical practice.

[13]  S. Loening,et al.  Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. , 2008, Cancer letters.

[14]  John V Frangioni,et al.  New technologies for human cancer imaging. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Michael Brady,et al.  Evaluating the Effectiveness of Using Standard Mammogram Form to Predict Breast Cancer Risk: Case-Control Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[16]  Mark Sh. Levin,et al.  Serum amyloid A enhances plasminogen activation: implication for a role in colon cancer. , 2008, Biochemical and biophysical research communications.

[17]  L. O’Driscoll,et al.  2‐D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins , 2007, Electrophoresis.

[18]  Lingyun Huang,et al.  Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum , 2007, Science in China Series C: Life Sciences.

[19]  Yanqing Ding,et al.  Protein and mRNA Characterization in Human Colorectal Carcinoma Cell Lines with Different Metastatic Potentials , 2007, Cancer investigation.

[20]  Chih-Hung Ku,et al.  Evaluation of Serum Amyloid A as a Biomarker for Gastric Cancer , 2006, Annals of Surgical Oncology.

[21]  Z. Ackerman,et al.  Expression of Serum Amyloid A, in Normal, Dysplastic, and Neoplastic Human Colonic Mucosa: Implication for a Role in Colonic Tumorigenesis , 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[22]  Kevin R Coombes,et al.  Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. , 2005, International journal of oncology.

[23]  Victor G Zgoda,et al.  Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1 , 2005, Proteomics.

[24]  David E. Misek,et al.  Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis , 2005, BMC Cancer.

[25]  S. Flibotte,et al.  Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. , 2005, Clinical chemistry.

[26]  Kevin R Coombes,et al.  Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  E. Diamandis.  Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker for Nasopharyngeal Carcinoma , 2004, Clinical Cancer Research.

[28]  M. Campa,et al.  Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma , 2004, Cancer.

[29]  Michael J Campa,et al.  Identification and validation of a potential lung cancer serum biomarker detected by matrix‐assisted laser desorption/ionization‐time of flight spectra analysis , 2003, Proteomics.

[30]  L. Tabár,et al.  Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening , 2003, The Lancet.

[31]  I. Glojnarić,et al.  Serum Amyloid A Protein (SAA) in Colorectal Carcinoma , 2001, Clinical chemistry and laboratory medicine.

[32]  S. Urieli-Shoval,et al.  Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states , 2000, Current opinion in hematology.

[33]  W. Odling-Smee,et al.  Screening for Breast Cancer , 1985, The Lancet.

[34]  M. Skinner,et al.  Acute‐Phase Proteins or Tumour Markers: The Role of SAA, SAP, CRP and CEA as Indicators of Metastasis in a Broad Spectrum of Neoplastic Diseases , 1984, Scandinavian journal of immunology.